Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Azedra
Metaiodobenzylguanidine (MIBG) is a radiopharmaceutical used in the diagnosis and treatment of certain types of neuroendocrine tumors. It is an analog of norepinephrine and is taken up by adrenergic tissue, including neuroendocrine tumors that express norepinephrine transporters. MIBG can be labeled with radioactive iodine (I-123 or I-131) for diagnostic imaging or therapy, respectively. I-123 MIBG is used in scintigraphy to locate tumors, while I-131 MIBG delivers targeted radiation therapy to cancerous cells.
Used for the diagnosis and treatment of certain neuroendocrine tumors.
Thrombocytopenia and neutropenia are common side effects, and patients should be monitored for myelosuppression. Potential for long-term hematologic toxicity and secondary myelodysplastic syndrome exists. Hepatotoxicity and hypertension can also occur.
Outcome:
Reduced effectiveness of MIBG therapy
Mechanism:
Competition for norepinephrine transporters
Outcome:
Increased risk of dehydration
Mechanism:
Additive diuretic effects
Outcome:
Reduced absorption of other medications
Mechanism:
Changes in stomach pH
Most likely new formulation: Targeted delivery systems utilizing nanoparticles or monoclonal antibodies (Year: 2028, 60% confidence)
Based on current clinical trial data and expanding indications, there is a 70% likelihood of MIBG therapy being approved for broader use in neuroendocrine tumors within the next 5 years.
Radiopharmaceutical, Diagnostic Agent, Therapeutic Agent
Benzylguanidine